Abstract
Wastewater-based surveillance has been proposed as a cost-effective toolset to generate data about public health status by detecting specific biomarkers in wastewater samples, as shown during the COVID-19 pandemic. In this work, we report on the performance of an extensive, building-by-building wastewater surveillance platform deployed across 38 locations of the largest private university system in Mexico, spanning 19 of the 32 states. Sampling took place weekly from January 2021 and June 2022. Data from 343 sampling sites was clustered by campus and by state and evaluated through its correlation with the seven-day average of daily new COVID-19 cases in each cluster. Statistically significant linear correlations (p-values below 0.05) were found in 25 of the 38 campuses and 13 of the 19 states. Moreover, to evaluate the effectiveness of epidemiologic containment measures taken by the institution across 2021 and the potential of university campuses as representative sampling points for surveillance in future public health emergencies in the Monterrey Metropolitan Area, correlation between new COVID-19 cases and viral loads in weekly wastewater samples was found to be stronger in Dulces Nombres, the largest wastewater treatment plant in the city (Pearson coefficient: 0.6456, p-value: 6.36710−8), than in the largest university campus in the study (Pearson coefficient: 0.4860, p-value: 8.288×10−5). However, when comparing the data after urban mobility returned to pre-pandemic levels, correlation levels in both locations became comparable (0.894 for the university campus and 0.865 for Dulces Nombres).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was funded by the Fundación FEMSA project entitled “Unidad de respuesta rápida al monitoreo de COVID19 por agua residual” (grant number NA). This work was supported by Tecnologico de Monterrey through the project Challenge-Based Research Funding Program 2022 (Muestreador Pasivo I026 - IAMSM005 - C4-T1 - T). The authors appreciate the support of Tecnologico de Monterrey for granting access to literature services and the scholarship awarded to Arnoldo Armenta-Castro (CVU: 1275527) and partially supporting this work under Sistema Nacional de Investigadores program awarded to Alberto Aguayo-Acosta (CVU: 403948), Mariel A. Oyervides-Muñoz (CVU: 422778), Roberto Parra-Saldívar (CVU: 35753) and Juan Eduardo Sosa-Hernández (CVU: 375202).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The document has the data used in the SI section.
